Picture loading failed.

Anti-CXCL10 therapeutic antibody (Pre-made Eldelumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Eldelumab (alternative identifier BMS-936557[1]) is a fully human monoclonal antibody (type IgG1 kappa)[2] that targets chemokine (C-X-C motif) ligand 10 (CXCL10)/Interferon-��-inducible protein-10 (IP-10)[2][1] designed for the treatment of Crohn's disease and ulcerative colitis.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-168-1mg 1mg 3090
GMP-Bios-ab-168-10mg 10mg 21890
GMP-Bios-ab-168-100mg 100mg 148000
GMP-Bios-ab-168-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-CXCL10 therapeutic antibody (Pre-made Eldelumab biosimilar,Whole mAb)
INN Name Eldelumab
TargetCXCL10
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2013
Year Recommended2014
CompaniesBristol-Myers Squibb;Medarex
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedCrohn's disease;Ulcerative colitis;Multiple sclerosis;Rheumatoid arthritis;Spinal cord injuries
Development TechMedarex UltiMAb Mouse